Literature DB >> 2872103

Purification of serotype 2 fimbriae of Bordetella pertussis and their identification as a mouse protective antigen.

J M Zhang, J L Cowell, A C Steven, C R Manclark.   

Abstract

Fimbriae were removed from Bordetella pertussis by mechanical shearing and purified by successive precipitations with ammonium sulfate, pH 6.0 phosphate buffer, and magnesium chloride. Electron microscopy showed the purified fimbriae to be long filamentous structures (5 nm in diameter) which aggregated into bundles at pH 6.0. Sodium dodecyl sulfate gel electrophoresis of the purified fimbriae gave a single protein subunit with a molecular weight of 22,000. The purified fimbriae did not have hemagglutinating activity when assayed with a variety of erythrocytes and were shown to be antigenically and structurally distinct from the filamentous hemagglutinin of B. pertussis. The purified fimbriae were identified as serotype 2 agglutinogens as antibody to the purified fimbriae agglutinated B. pertussis strains serotyped as 1.2.4, 1.2.3, or 1.2.3.6, but did not agglutinate serotypes 1.3.6. Immunization of mice with the purified fimbriae (14 micrograms) protected them from a lethal respiratory infection with strain 18323 (agglutinogen serotype 1.2.3.4.6) or with strain 432 (serotype 1.3.6). Immunization of mice with purified fimbriae containing 0.02% LPF also protected them from a lethal intracerebral infection with 18323. The ED50 was about 13 micrograms. Fimbriae containing less than 0.005% LPF did not protect mice from intracerebral challenge.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2872103

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  8 in total

Review 1.  Pertussis: the disease and new diagnostic methods.

Authors:  R L Friedman
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

2.  Preparation of filamentous hemagglutinin from Bordetella pertussis and assay for serum antibodies to filamentous hemagglutinin and pertussis toxin for clinical and public health laboratories.

Authors:  K H Wong; S K Skelton
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

3.  Simple, efficient purification of filamentous hemagglutinin and pertussis toxin from Bordetella pertussis by hydrophobic and affinity interaction.

Authors:  S K Skelton; K H Wong
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

4.  Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies.

Authors:  Z M Li; M J Brennan; J L David; P H Carter; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

5.  Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis.

Authors:  M J Brennan; Z M Li; J L Cowell; M E Bisher; A C Steven; P Novotny; C R Manclark
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

6.  Purification and characterization of serotype 6 fimbriae from Bordetella pertussis and comparison of their properties with serotype 2 fimbriae.

Authors:  J L Cowell; J M Zhang; A Urisu; A Suzuki; A C Steven; T Liu; T Y Liu; C R Manclark
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

7.  Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.

Authors:  B M van den Berg; H Beekhuizen; F R Mooi; R van Furth
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

Review 8.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.